Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 79Myelodysplastic Syndromes 42Leukemia 23Leukemia, Myelomonocytic, Chronic 20Congenital Abnormalities 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Recurrence 7Neoplasms 7Myeloproliferative Disorders 7Blast Crisis 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myeloid, Accelerated Phase 5Carcinoma, Non-Small-Cell Lung 5Thrombocythemia, Essential 4Primary Myelofibrosis 4Polycythemia Vera 4Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lung Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Burkitt Lymphoma 3Anemia, Refractory, with Excess of Blasts 3Anemia, Refractory 3Small Cell Lung Carcinoma 2Neuroblastoma 2Neoplasm Metastasis 2Mesothelioma, Malignant 2

Interventions

ruxolitinib 4Imatinib Mesylate 3ponatinib 2nilotinib 2Azacitidine 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1bosutinib 1Zoledronic Acid 1SCIO-469 1Lenalidomide 1Denosumab 1Decitabine 1Clofarabine 1CPI-0610 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bone Marrow Diseases × Decitabine × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡